CoChat
Sign Up
Cited by 125

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Epilepsy in the mTORopathies: opportunities for precision medicine

Moloney, Patrick B, Cavalleri, Gianpiero L, Delanty, Norman·2021·Brain Communications
DOI 10.1093/braincomms/fcab222PMC PMC8495134
Open this paper in CoChat — free account

Abstract

The mechanistic target of rapamycin signalling pathway serves as a ubiquitous regulator of cell metabolism, growth, proliferation and survival. The main cellular activity of the mechanistic target of rapamycin cascade funnels through mechanistic target of rapamycin complex 1, which is inhibited by rapamycin, a macrolide compound produced by the bacterium Streptomyces hygroscopicus. Pathogenic variants in genes encoding upstream regulators of mechanistic target of rapamycin complex 1 cause epilepsies and neurodevelopmental disorders. Tuberous sclerosis complex is a multisystem disorder caused by mutations in mechanistic target of rapamycin regulators TSC1 or TSC2, with prominent neurological manifestations including epilepsy, focal cortical dysplasia and neuropsychiatric disorders. Focal cortical dysplasia type II results from somatic brain mutations in mechanistic target of rapamycin pathway activators MTOR, AKT3, PIK3CA and RHEB and is a major cause of drug-resistant epilepsy. DEPDC5, NPRL2 and NPRL3 code for subunits of the GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1), the principal amino acid-sensing regulator of mechanistic target of rapamycin complex 1. Germline pathogenic variants in GATOR1 genes cause non-lesional focal epilepsies and epilepsies associated with malformations of cortical development. Collectively, the mTORopathies are characterized by excessive mechanistic target of rapamycin pathway activation and drug-resistant epilepsy. In the first large-scale precision medicine trial in a genetically mediated epilepsy, everolimus (a synthetic analogue of rapamycin) was effective at reducing seizure frequency in people with tuberous sclerosis complex. Rapamycin reduced seizures in rodent models of DEPDC5-related epilepsy and focal cortical dysplasia type II. This review outlines a personalized medicine approach to the management of epilepsies in the mTORopathies. We advocate for early diagnostic sequencing of mechanistic target of rapamycin pathway genes in drug-resistant epilepsy, as identification of a pathogenic variant may point to an occult dysplasia in apparently non-lesional epilepsy or may uncover important prognostic information including, an increased risk of sudden unexpected death in epilepsy in the GATORopathies or favourable epilepsy surgery outcomes in focal cortical dysplasia type II due to somatic brain mutations. Lastly, we discuss the potential therapeutic application of mechanistic target of rapamycin inhibitors for drug-resistant seizures in GATOR1-related epilepsies and focal cortical dysplasia type II.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/braincomms/fcab222

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract
Graphical Abstract CC BY · PubMed Central
Figure 1 The mTOR cascade and its regulators. Mechanistic target of rapamycin (mTOR) combines with protein binding partners to form mTOR complex 1 (mTORC1). The downstream substrates of mTORC1 signalling include ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1). Rapamycin inhibits mTORC1 signalling by binding with FK506 binding protein 1 A 12 kDa (FKBP12). Three pathways converge to regulate mTORC1 signalling. Hamartin (TSC1), tuberin (TSC2) and TBC1 domain family member 7 (TBC1D7) form a protein complex that indirectly inhibits mTORC1 signalling via Ras homologue enriched in brain (Rheb). (A) Growth factors stimulate phosphoinositide 3-kinase (PI3K) to trigger phosphoinositide-dependent kinase 1 (PDK1) to phosphorylate and activate Akt. TSC2 is repressed by Akt activation, which has a disinhibitory effect on mTORC1 signalling. Phosphatase and tensin homologue (PTEN) is a negative regulator of the PI3K-Akt pathway. (B) The energy-sensing arm is regulated by the STE20-related kinase adaptor alpha (STRADα) and liver kinase B (LKB) complex. In response to depleted ATP, the STRADα/LKB complex inhibits mTORC1 signalling by activating TSC2 via phosphorylation of adenosine monophosphate-activated kinase (AMPK). (C) The amino acid-sensing pathway is regulated by GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1). GATOR1 is composed of three subunits: Dishevelled, Egl-10, and Pleckstrin domain-containing protein 5 (DEPDC5); nitrogen permease regulator-like 2 and 3 (NPRL2, NPRL3). The GATOR2 complex inhibits GATOR1 in response to increasing amino acid levels, resulting in mTORC1 disinhibition, facilitating pathways for cell growth. When amino acid levels are low GATOR1 directly inhibits mTORC1 activity. The KICSTOR (KPTN, ITFG2, C12orf66 and SZT2-containing regulator of mTORC1) complex scaffolds GATOR1 to the lysosomal surface (adapted from Peter B. Crino’s review7 with permission from Springer Nature).
Figure 1 The mTOR cascade and its regulators. Mechanistic target of rapamycin (mTOR) combines with protein binding partners to form mTOR complex 1 (mTORC1). The downstream substrates of mTORC1 signalling include ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1). Rapamycin inhibits mTORC1 signalling by binding with FK506 binding protein 1 A 12 kDa (FKBP12). Three pathways converge to regulate mTORC1 signalling. Hamartin (TSC1), tuberin (TSC2) and TBC1 domain family member 7 (TBC1D7) form a protein complex that indirectly inhibits mTORC1 signalling via Ras homologue enriched in brain (Rheb). (A) Growth factors stimulate phosphoinositide 3-kinase (PI3K) to trigger phosphoinositide-dependent kinase 1 (PDK1) to phosphorylate and activate Akt. TSC2 is repressed by Akt activation, which has a disinhibitory effect on mTORC1 signalling. Phosphatase and tensin homologue (PTEN) is a negative regulator of the PI3K-Akt pathway. (B) The energy-sensing arm is regulated by the STE20-related kinase adaptor alpha (STRADα) and liver kinase B (LKB) complex. In response to depleted ATP, the STRADα/LKB complex inhibits mTORC1 signalling by activating TSC2 via phosphorylation of adenosine monophosphate-activated kinase (AMPK). (C) The amino acid-sensing pathway is regulated by GTPase-activating protein (GAP) activity towards Rags 1 complex (GATOR1). GATOR1 is composed of three subunits: Dishevelled, Egl-10, and Pleckstrin domain-containing protein 5 (DEPDC5); nitrogen permease regulator-like 2 and 3 (NPRL2, NPRL3). The GATOR2 complex inhibits GATOR1 in response to increasing amino acid levels, resulting in mTORC1 disinhibition, facilitating pathways for cell growth. When amino acid levels are low GATOR1 directly inhibits mTORC1 activity. The KICSTOR (KPTN, ITFG2, C12orf66 and SZT2-containing regulator of mTORC1) complex scaffolds GATOR1 to the lysosomal surface (adapted from Peter B. Crino’s review7 with permission from Springer Nature).CC BY · PubMed Central
Figure 2 A personalised medicine approach to the management of tuberous sclerosis complex-related epilepsy. This figure outlines a therapeutic and prognostic framework, utilizing genetic and molecular data for the management of TSC-related epilepsy. Early genetic testing for TSC1 or TSC2 mutations is recommended for infants with phenotypic features of TSC. TSC2 mutations are associated with a more severe neurological phenotype. In pre-symptomatic TSC, serial EEG monitoring is recommended, as pre-emptive vigabatrin at the onset of epileptiform abnormalities is associated with better long-term epilepsy outcomes. Evidence-based treatment options for TSC-related DRE include everolimus, CBD and tuberectomy with resection of surrounding perituberal tissue. Early treatment with everolimus in seizure-naïve TSC patients may improve long-term epilepsy and cognitive outcomes. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. ASM, anti-seizure medication; CBD, cannabidiol; DRE, drug-resistant epilepsy; mTORi, mechanistic target of rapamycin inhibitor; TSC, tuberous sclerosis complex.
Figure 2 A personalised medicine approach to the management of tuberous sclerosis complex-related epilepsy. This figure outlines a therapeutic and prognostic framework, utilizing genetic and molecular data for the management of TSC-related epilepsy. Early genetic testing for TSC1 or TSC2 mutations is recommended for infants with phenotypic features of TSC. TSC2 mutations are associated with a more severe neurological phenotype. In pre-symptomatic TSC, serial EEG monitoring is recommended, as pre-emptive vigabatrin at the onset of epileptiform abnormalities is associated with better long-term epilepsy outcomes. Evidence-based treatment options for TSC-related DRE include everolimus, CBD and tuberectomy with resection of surrounding perituberal tissue. Early treatment with everolimus in seizure-naïve TSC patients may improve long-term epilepsy and cognitive outcomes. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. ASM, anti-seizure medication; CBD, cannabidiol; DRE, drug-resistant epilepsy; mTORi, mechanistic target of rapamycin inhibitor; TSC, tuberous sclerosis complex.CC BY · PubMed Central
Figure 3 A personalised medicine approach to the management of GATOR1-related epilepsies. Early diagnostic sequencing of mTOR pathway genes is recommended in non-lesional epilepsies and in epilepsies due to FCD or HME. LoF DEPDC5 and NPRL3 variants are associated with severe epilepsy phenotypes. Treatment options for GATOR1-related DRE include epilepsy surgery and potentially, mTOR inhibitors. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. FCD, focal cortical dysplasia; GATOR1, GAP activity towards Rags 1 complex; HME, hemimegalencephaly; LoF, loss-of-function; mTORi, mechanistic target of rapamycin inhibitor; SUDEP, sudden unexpected death in epilepsy.
Figure 3 A personalised medicine approach to the management of GATOR1-related epilepsies. Early diagnostic sequencing of mTOR pathway genes is recommended in non-lesional epilepsies and in epilepsies due to FCD or HME. LoF DEPDC5 and NPRL3 variants are associated with severe epilepsy phenotypes. Treatment options for GATOR1-related DRE include epilepsy surgery and potentially, mTOR inhibitors. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. FCD, focal cortical dysplasia; GATOR1, GAP activity towards Rags 1 complex; HME, hemimegalencephaly; LoF, loss-of-function; mTORi, mechanistic target of rapamycin inhibitor; SUDEP, sudden unexpected death in epilepsy.CC BY · PubMed Central
Figure 4 A personalised medicine approach to the management of epilepsy due to FCD type II and hemimegalencephaly. Epilepsy surgery for FCD type II and HME due to pathogenic variants in mTOR pathway genes is associated with good surgical outcomes. CSF liquid biopsy represents a less invasive option for identification of somatic mutations in cases without detectable mTOR pathway germline mutations. mTOR inhibitors may offer an alternative therapeutic strategy for individuals with inaccessible lesions or persistent seizures after surgery. PIK3CA and AKT inhibitors are promising targeted therapies for individuals with PIKC3A- and AKT3-associated MCD. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. FCD, focal cortical dysplasia; HME, hemimegalencephaly; MCD, malformation of cortical development; mTORi, mechanistic target of rapamycin inhibitor.
Figure 4 A personalised medicine approach to the management of epilepsy due to FCD type II and hemimegalencephaly. Epilepsy surgery for FCD type II and HME due to pathogenic variants in mTOR pathway genes is associated with good surgical outcomes. CSF liquid biopsy represents a less invasive option for identification of somatic mutations in cases without detectable mTOR pathway germline mutations. mTOR inhibitors may offer an alternative therapeutic strategy for individuals with inaccessible lesions or persistent seizures after surgery. PIK3CA and AKT inhibitors are promising targeted therapies for individuals with PIKC3A- and AKT3-associated MCD. Evidence-based recommendations are highlighted in blue and potential future applications are highlighted in gold. FCD, focal cortical dysplasia; HME, hemimegalencephaly; MCD, malformation of cortical development; mTORi, mechanistic target of rapamycin inhibitor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 154

  1. Helbig, 2016, Diagnostic exome sequencing provides a molecular diagnosis for a significant proportion of patients with epilepsy, Genet Med, 18, 898, 10.1038/gim.2015.186 · DOI
  2. Benson, 2020, A comparison of genomic diagnostics in adults and children with epilepsy and comorbid intellectual disability, Eur J Hum Genet, 28, 1066, 10.1038/s41431-020-0610-3 · DOI
  3. Krenn, 2020, Diagnostic exome sequencing in non-acquired focal epilepsies highlights a major role of GATOR1 complex genes, J Med Genet, 57, 624, 10.1136/jmedgenet-2019-106658 · DOI
  4. Kearney, 2019, Tackling epilepsy with high-definition precision medicine: A review, JAMA Neurol, 76, 1109, 10.1001/jamaneurol.2019.2384 · DOI
  5. Ellis, 2020, Epilepsy genetics: Clinical impacts and biological insights, Lancet Neurol, 19, 93, 10.1016/S1474-4422(19)30269-8 · DOI
  6. Crino, 2016, The mTOR signalling cascade: Paving new roads to cure neurological disease, Nat Rev Neurol, 12, 379, 10.1038/nrneurol.2016.81 · DOI · Paper page
  7. Henske, 2016, Tuberous sclerosis complex, Nat Rev Dis Primers, 2, 16035, 10.1038/nrdp.2016.35 · DOI
  8. Baldassari, 2019, The landscape of epilepsy-related GATOR1 variants, Genet Med, 21, 398, 10.1038/s41436-018-0060-2 · DOI
  9. French, 2016, Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): A phase 3, randomised, double-blind, placebo-controlled study, Lancet, 388, 2153, 10.1016/S0140-6736(16)31419-2 · DOI · Paper page
  10. Laplante, 2012, mTOR signaling in growth control and disease, Cell, 149, 274, 10.1016/j.cell.2012.03.017 · DOI · Paper page
  11. Lasarge, 2014, Mechanisms regulating neuronal excitability and seizure development following mTOR pathway hyperactivation, Front Mol Neurosci, 7, 18, 10.3389/fnmol.2014.00018 · DOI
  12. Jacinto, 2004, Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive, Nat Cell Biol, 6, 1122, 10.1038/ncb1183 · DOI
  13. Lipton, 2014, The neurology of mTOR, Neuron, 84, 275, 10.1016/j.neuron.2014.09.034 · DOI
  14. Wolfson, 2017, KICSTOR recruits GATOR1 to the lysosome and is necessary for nutrients to regulate mTORC1, Nature, 543, 438, 10.1038/nature21423 · DOI
  15. Baldassari, 2016, GATOR1 complex: The common genetic actor in focal epilepsies, J Med Genet, 53, 503, 10.1136/jmedgenet-2016-103883 · DOI · Paper page
  16. Parker, 2013, Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder, Sci Transl Med, 5, 182ra53, 10.1126/scitranslmed.3005271 · DOI
  17. Gordo, 2018, mTOR mutations in Smith-Kingsmore syndrome: Four additional patients and a review, Clin Genet, 93, 762, 10.1111/cge.13135 · DOI
  18. Nakamura, 2014, AKT3 and PIK3R2 mutations in two patients with megalencephaly-related syndromes: MCAP and MPPH, Clin Genet, 85, 396, 10.1111/cge.12188 · DOI
  19. Severino, 2020, Definitions and classification of malformations of cortical development: Practical guidelines, Brain, 143, 2874, 10.1093/brain/awaa174 · DOI
  20. Lee, 2020, Genetic characterization identifies bottom-of-sulcus dysplasia as an mTORopathy, Neurology, 95, e2542, 10.1212/WNL.0000000000010670 · DOI
  21. Jansen, 2015, PI3K/AKT pathway mutations cause a spectrum of brain malformations from megalencephaly to focal cortical dysplasia, Brain, 138, 1613, 10.1093/brain/awv045 · DOI · Paper page
  22. Lim, 2015, Brain somatic mutations in MTOR cause focal cortical dysplasia type II leading to intractable epilepsy, Nat Med, 21, 395, 10.1038/nm.3824 · DOI
  23. Lee, 2012, De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly, Nat Genet, 44, 941, 10.1038/ng.2329 · DOI · Paper page
  24. D’Gama, 2017, Somatic mutations activating the mTOR pathway in dorsal telencephalic progenitors cause a continuum of cortical dysplasias, Cell Rep, 21, 3754, 10.1016/j.celrep.2017.11.106 · DOI
  25. D'Gama, 2015, Mammalian target of rapamycin pathway mutations cause hemimegalencephaly and focal cortical dysplasia, Ann Neurol, 77, 720, 10.1002/ana.24357 · DOI
  26. Knudson, 1971, Mutation and cancer: Statistical study of retinoblastoma, Proc Natl Acad Sci U S A, 68, 820, 10.1073/pnas.68.4.820 · DOI · Paper page
  27. Lee, 2019, Second-hit DEPDC5 mutation is limited to dysmorphic neurons in cortical dysplasia type IIA, Ann Clin Transl Neurol, 6, 1338, 10.1002/acn3.50815 · DOI
  28. Baulac, 2015, Familial focal epilepsy with focal cortical dysplasia due to DEPDC5 mutations, Ann Neurol, 77, 675, 10.1002/ana.24368 · DOI
  29. Abs, 2013, TORC1-dependent epilepsy caused by acute biallelic Tsc1 deletion in adult mice, Ann Neurol, 74, 569, 10.1002/ana.23943 · DOI
  30. Baybis, 2004, mTOR cascade activation distinguishes tubers from focal cortical dysplasia, Ann Neurol, 56, 478, 10.1002/ana.20211 · DOI
  31. Ljungberg, 2006, Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia, Ann Neurol, 60, 420, 10.1002/ana.20949 · DOI
  32. Schick, 2007, Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells, Brain Pathol, 17, 165, 10.1111/j.1750-3639.2007.00059.x · DOI
  33. Cepeda, 2003, Morphological and electrophysiological characterization of abnormal cell types in pediatric cortical dysplasia, J Neurosci Res, 72, 472, 10.1002/jnr.10604 · DOI
  34. Cepeda, 2006, Epileptogenesis in pediatric cortical dysplasia: The dysmature cerebral developmental hypothesis, Epilepsy Behav, 9, 219, 10.1016/j.yebeh.2006.05.012 · DOI
  35. Talos, 2008, Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers, Ann Neurol, 63, 454, 10.1002/ana.21342 · DOI · Paper page
  36. Iffland, 2017, Focal cortical dysplasia: Gene mutations, cell signaling, and therapeutic implications, Annu Rev Pathol, 12, 547, 10.1146/annurev-pathol-052016-100138 · DOI
  37. Cepeda, 2014, Pacemaker GABA synaptic activity may contribute to network synchronization in pediatric cortical dysplasia, Neurobiol Dis, 62, 208, 10.1016/j.nbd.2013.10.001 · DOI
  38. Nguyen, 2015, mTOR inhibition suppresses established epilepsy in a mouse model of cortical dysplasia, Epilepsia, 56, 636, 10.1111/epi.12946 · DOI
  39. Zeng, 2008, Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex, Ann Neurol, 63, 444, 10.1002/ana.21331 · DOI · Paper page
  40. Zeng, 2011, Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex, Hum Mol Genet, 20, 445, 10.1093/hmg/ddq491 · DOI
  41. Hsieh, 2016, Convulsive seizures from experimental focal cortical dysplasia occur independently of cell misplacement, Nat Commun, 7, 11753, 10.1038/ncomms11753 · DOI
  42. Marsan, 2016, Depdc5 knockout rat: A novel model of mTORopathy, Neurobiol Dis, 89, 180, 10.1016/j.nbd.2016.02.010 · DOI
  43. Yuskaitis, 2018, A mouse model of DEPDC5-related epilepsy: Neuronal loss of Depdc5 causes dysplastic and ectopic neurons, increased mTOR signaling, and seizure susceptibility, Neurobiol Dis, 111, 91, 10.1016/j.nbd.2017.12.010 · DOI
  44. Hu, 2018, Somatic Depdc5 deletion recapitulates electroclinical features of human focal cortical dysplasia type IIA, Ann Neurol, 84, 140, 10.1002/ana.25272 · DOI
  45. Klofas, 2020, Prevention of premature death and seizures in a Depdc5 mouse epilepsy model through inhibition of mTORC1, Hum Mol Genet, 29, 1365, 10.1093/hmg/ddaa068 · DOI
  46. Hoogeveen-Westerveld, 2011, Functional assessment of variants in the TSC1 and TSC2 genes identified in individuals with tuberous sclerosis complex, Hum Mutat, 32, 424, 10.1002/humu.21451 · DOI
  47. van Kranenburg, 2015, Preliminary functional assessment and classification of DEPDC5 variants associated with focal epilepsy, Hum Mutat, 36, 200, 10.1002/humu.22723 · DOI
  48. Dawson, 2020, Functional screening of GATOR1 complex variants reveals a role for mTORC1 deregulation in FCD and focal epilepsy, Neurobiol Dis, 134, 104640, 10.1016/j.nbd.2019.104640 · DOI
  49. Mirzaa, 2016, Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism, JAMA Neurol, 73, 836, 10.1001/jamaneurol.2016.0363 · DOI
  50. Zhao, 2019, A brain somatic RHEB doublet mutation causes focal cortical dysplasia type II, Exp Mol Med, 51, 1, 10.1038/s12276-019-0277-4 · DOI
  51. Sim, 2016, Familial cortical dysplasia caused by mutation in the mammalian target of rapamycin regulator NPRL3, Ann Neurol, 79, 132, 10.1002/ana.24502 · DOI
  52. Scerri, 2015, Familial cortical dysplasia type IIA caused by a germline mutation in DEPDC5, Ann Clin Transl Neurol, 2, 575, 10.1002/acn3.191 · DOI
  53. Weckhuysen, 2016, Involvement of GATOR complex genes in familial focal epilepsies and focal cortical dysplasia, Epilepsia, 57, 994, 10.1111/epi.13391 · DOI
  54. Bi, 2016, Whole exome sequencing identifies the first STRADA point mutation in a patient with polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome (PMSE), Am J Med Genet A, 170, 2181, 10.1002/ajmg.a.37727 · DOI
  55. Nelson, 2018, Novel homozygous deletion in STRADA gene associated with polyhydramnios, megalencephaly, and epilepsy in 2 siblings: Implications for diagnosis and treatment, J Child Neurol, 33, 925, 10.1177/0883073818802724 · DOI
  56. Alsaif, 2021, Two further cases of polyhydramnios, megalencephaly, and symptomatic epilepsy syndrome, caused by a truncating variant in STRADA, Am J Med Genet A, 185, 604, 10.1002/ajmg.a.61990 · DOI
  57. Aerden, 2021, Homozygous missense STRADA mutation in a patient with polyhydramnios, megalencephaly and symptomatic epilepsy syndrome, Clin Dysmorphol, 30, 121, 10.1097/MCD.0000000000000368 · DOI
  58. Orlova, 2010, STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice, J Clin Invest, 120, 1591, 10.1172/JCI41592 · DOI
  59. Dabora, 2001, Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs, Am J Hum Genet, 68, 64, 10.1086/316951 · DOI
  60. Tyburczy, 2015, Mosaic and intronic mutations in TSC1/TSC2 explain the majority of TSC patients with no mutation identified by conventional testing, PLoS Genet, 11, e1005637, 10.1371/journal.pgen.1005637 · DOI
  61. Holmes, 2007, Tuberous sclerosis complex and epilepsy: Recent developments and future challenges, Epilepsia, 48, 617, 10.1111/j.1528-1167.2007.01035.x · DOI
  62. Chu-Shore, 2009, The natural history of epilepsy in tuberous sclerosis complex, Epilepsia, 51, 1236, 10.1111/j.1528-1167.2009.02474.x · DOI
  63. Joinson, 2003, Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex, Psychol Med, 33, 335, 10.1017/S0033291702007092 · DOI · Paper page
  64. Numis, 2011, Identification of risk factors for autism spectrum disorders in tuberous sclerosis complex, Neurology, 76, 981, 10.1212/WNL.0b013e3182104347 · DOI
  65. van Eeghen, 2012, Genotype and cognitive phenotype of patients with tuberous sclerosis complex, Eur J Hum Genet, 20, 510, 10.1038/ejhg.2011.241 · DOI
  66. Ogórek, 2020, TSC2 pathogenic variants are predictive of severe clinical manifestations in TSC infants: Results of the EPISTOP study, Genet Med, 22, 1489, 10.1038/s41436-020-0823-4 · DOI
  67. Salussolia, 2019, Genetic etiologies, diagnosis, and treatment of tuberous sclerosis complex, Annu Rev Genomics Hum Genet, 20, 217, 10.1146/annurev-genom-083118-015354 · DOI · Paper page
  68. Ruppe, 2014, Developmental brain abnormalities in tuberous sclerosis complex: A comparative tissue analysis of cortical tubers and perituberal cortex, Epilepsia, 55, 539, 10.1111/epi.12545 · DOI
  69. Liu, 2020, Resective epilepsy surgery in tuberous sclerosis complex: A nationwide multicentre retrospective study from China, Brain, 143, 570, 10.1093/brain/awz411 · DOI
  70. Chu-Shore, 2009, Progressive multifocal cystlike cortical tubers in tuberous sclerosis complex: Clinical and neuropathologic findings, Epilepsia, 50, 2648, 10.1111/j.1528-1167.2009.02193.x · DOI
  71. Wu, 2019, Scalp EEG spikes predict impending epilepsy in TSC infants: A longitudinal observational study, Epilepsia, 60, 2428, 10.1111/epi.16379 · DOI
  72. Kotulska, 2021, Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial, Ann Neurol, 89, 304, 10.1002/ana.25956 · DOI
  73. MacKeigan, 2015, Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex, Neuro Oncol, 17, 1550, 10.1093/neuonc/nov152 · DOI
  74. Hudes, 2007, Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma, N Engl J Med, 356, 2271, 10.1056/NEJMoa066838 · DOI
  75. Mita, 2008, Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies, J Clin Oncol, 26, 361, 10.1200/JCO.2007.12.0345 · DOI
  76. Bissler, 2008, Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis, N Engl J Med, 358, 140, 10.1056/NEJMoa063564 · DOI
  77. Franz, 2013, Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): A multicentre, randomised, placebo-controlled phase 3 trial, Lancet, 381, 125, 10.1016/S0140-6736(12)61134-9 · DOI · Paper page
  78. Bissler, 2013, Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): A multicentre, randomised, double-blind, placebo-controlled trial, Lancet, 381, 817, 10.1016/S0140-6736(12)61767-X · DOI
  79. Franz, 2018, Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial, Neurol Clin Pract, 8, 412, 10.1212/CPJ.0000000000000514 · DOI · Paper page
  80. Kingswood, 2021, TuberOus SClerosis registry to increAse disease awareness (TOSCA) post-authorisation safety study of everolimus in patients with tuberous sclerosis complex, Front Neurol, 12, 630378, 10.3389/fneur.2021.630378 · DOI
  81. Willems, 2021, Efficacy, retention and tolerability of everolimus in patients with tuberous sclerosis complex: A survey-based study on patients' perspectives, CNS Drugs, 1107, 10.1007/s40263-021-00839-4 · DOI
  82. Shipkova, 2016, Therapeutic drug monitoring of everolimus: A consensus report, Ther Drug Monit, 38, 143, 10.1097/FTD.0000000000000260 · DOI
  83. Franz, 2016, Long-term use of everolimus in patients with tuberous sclerosis complex: Final results from the EXIST-1 study, PLoS One, 11, e0158476, 10.1371/journal.pone.0158476 · DOI
  84. Mingarelli, 2018, Dramatic relapse of seizures after everolimus withdrawal, Eur J Paediatr Neurol, 22, 203, 10.1016/j.ejpn.2017.07.018 · DOI
  85. Ventura-Aguiar, 2016, Safety of mTOR inhibitors in adult solid organ transplantation, Expert Opin Drug Saf, 15, 303, 10.1517/14740338.2016.1132698 · DOI
  86. Curatolo, 2015, Neurological and neuropsychiatric aspects of tuberous sclerosis complex, Lancet Neurol, 14, 733, 10.1016/S1474-4422(15)00069-1 · DOI · Paper page
  87. Rensing, 2015, Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex, Epilepsia, 56, 1088, 10.1111/epi.13031 · DOI
  88. Formisano, 2020, Mechanisms of resistance to mTOR inhibitors, Crit Rev Oncol Hematol, 147, 102886, 10.1016/j.critrevonc.2020.102886 · DOI
  89. Bonazzi, 2020, Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders, J Med Chem, 63, 1068, 10.1021/acs.jmedchem.9b01398 · DOI
  90. Thiele, 2021, Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: A placebo-controlled randomized clinical trial, JAMA Neurol, 285, 10.1001/jamaneurol.2020.4607 · DOI · Paper page
  91. Ebrahimi-Fakhari, 2020, Cannabidiol elevates mechanistic target of rapamycin inhibitor levels in patients with tuberous sclerosis complex, Pediatr Neurol, 105, 59, 10.1016/j.pediatrneurol.2019.11.017 · DOI
  92. Overwater, 2019, A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex, Neurology, 93, e200, 10.1212/WNL.0000000000007749 · DOI
  93. Randell, 2016, The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial, Trials, 17, 398, 10.1186/s13063-016-1446-6 · DOI
  94. Saffari, 2019, Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study, Orphanet J Rare Dis, 14, 96, 10.1186/s13023-019-1077-6 · DOI
  95. Way, 2012, The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex, Hum Mol Genet, 21, 3226, 10.1093/hmg/dds156 · DOI
  96. Kingsmore, 2019, A randomized, controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome sequencing in ill infants, Am J Hum Genet, 105, 719, 10.1016/j.ajhg.2019.08.009 · DOI
  97. Cheah, 2021, Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin, Sci Adv, 7, eabb1703, 10.1126/sciadv.abb1703 · DOI · Paper page
  98. Dibbens, 2013, Mutations in DEPDC5 cause familial focal epilepsy with variable foci, Nat Genet, 45, 546, 10.1038/ng.2599 · DOI · Paper page
  99. 2017, Ultra-rare genetic variation in common epilepsies: a case-control sequencing study, Lancet Neurol, 16, 135, 10.1016/S1474-4422(16)30359-3 · DOI
  100. 2019, Ultra-rare genetic variation in the epilepsies: A whole-exome sequencing study of 17,606 individuals, Am J Hum Genet, 105, 267, 10.1016/j.ajhg.2019.05.020 · DOI
  101. Martin, 2014, A recurrent mutation in DEPDC5 predisposes to focal epilepsies in the French-Canadian population, Clin Genet, 86, 570, 10.1111/cge.12311 · DOI
  102. Picard, 2014, DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy, Neurology, 82, 2101, 10.1212/WNL.0000000000000488 · DOI
  103. Korenke, 2016, Nocturnal frontal lobe epilepsy caused by a mutation in the GATOR1 complex gene NPRL3, Epilepsia, 57, e60, 10.1111/epi.13307 · DOI
  104. Pippucci, 2015, Epilepsy with auditory features: A heterogeneous clinico-molecular disease, Neurol Genet, 1, e5, 10.1212/NXG.0000000000000005 · DOI
  105. Carvill, 2015, Epileptic spasms are a feature of DEPDC5 mTORopathy, Neurol Genet, 1, e17, 10.1212/NXG.0000000000000016 · DOI · Paper page
  106. Lal, 2014, DEPDC5 mutations in genetic focal epilepsies of childhood, Ann Neurol, 75, 788, 10.1002/ana.24127 · DOI
  107. Scheffer, 2014, Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations, Ann Neurol, 75, 782, 10.1002/ana.24126 · DOI
  108. Canavati, 2019, Inclusion of hemimegalencephaly into the phenotypic spectrum of NPRL3 pathogenic variants in familial focal epilepsy with variable foci, Epilepsia, 60, e67, 10.1111/epi.15665 · DOI
  109. Burger, 2017, Autistic siblings with novel mutations in two different genes: Insight for genetic workups of autistic siblings and connection to mitochondrial dysfunction, Front Pediatr, 5, 219, 10.3389/fped.2017.00219 · DOI
  110. Bagnall, 2016, Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy, Ann Neurol, 79, 522, 10.1002/ana.24596 · DOI
  111. Kowalczyk, 2012, Nprl3 is required for normal development of the cardiovascular system, Mamm Genome, 23, 404, 10.1007/s00335-012-9398-y · DOI
  112. Hughes, 2017, Knockout of the epilepsy gene Depdc5 in mice causes severe embryonic dysmorphology with hyperactivity of mTORC1 signalling, Sci Rep, 7, 12618, 10.1038/s41598-017-12574-2 · DOI
  113. Nascimento, 2015, Two definite cases of sudden unexpected death in epilepsy in a family with a DEPDC5 mutation, Neurol Genet, 1, e28, 10.1212/NXG.0000000000000028 · DOI
  114. Vawter-Lee, 2019, Clinical Letter: A case report of targeted therapy with sirolimus for NPRL3 epilepsy, Seizure, 73, 43, 10.1016/j.seizure.2019.10.007 · DOI
  115. Stevelink, 2018, Epilepsy surgery for patients with genetic refractory epilepsy: a systematic review, Epileptic Disord, 20, 99, 10.1684/epd.2018.0959 · DOI
  116. Blumcke, 2017, Histopathological findings in brain tissue obtained during epilepsy surgery, N Engl J Med, 377, 1648, 10.1056/NEJMoa1703784 · DOI
  117. Marsan, 2018, Review: Mechanistic target of rapamycin (mTOR) pathway, focal cortical dysplasia and epilepsy, Neuropathol Appl Neurobiol, 44, 6, 10.1111/nan.12463 · DOI
  118. Xu, 2019, mTOR inhibitors as a new therapeutic strategy in treatment resistant epilepsy in hemimegalencephaly: A case report, J Child Neurol, 34, 132, 10.1177/0883073818813238 · DOI
  119. Venot, 2018, Targeted therapy in patients with PIK3CA-related overgrowth syndrome, Nature, 558, 540, 10.1038/s41586-018-0217-9 · DOI
  120. Forde, 2021, Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome, Orphanet J Rare Dis, 16, 109, 10.1186/s13023-021-01745-0 · DOI
  121. Pan, 2015, Brain tumor mutations detected in cerebral spinal fluid, Clin Chem, 61, 514, 10.1373/clinchem.2014.235457 · DOI
  122. Kim, 2021, Detection of brain somatic mutations in cerebrospinal fluid from refractory epilepsy patients, Ann Neurol, 89, 1248, 10.1002/ana.26080 · DOI
  123. Müller, 2021, Systematic review of N-of-1 studies in rare genetic neurodevelopmental disorders: The power of 1, Neurology, 96, 529, 10.1212/WNL.0000000000011597 · DOI
  124. Blackston, 2019, Comparison of aggregated N-of-1 trials with parallel and crossover randomized controlled trials using simulation studies, Healthcare (Basel), 7, 137, 10.3390/healthcare7040137 · DOI
  125. Tidball, 2020, Variant-specific changes in persistent or resurgent sodium current in SCN8A-related epilepsy patient-derived neurons, Brain, 143, 3025, 10.1093/brain/awaa247 · DOI
  126. Sidira, 2021, Hemimegalencephaly and tuberous sclerosis complex: A rare yet challenging association, Eur J Paediatr Neurol, 30, 58, 10.1016/j.ejpn.2020.12.007 · DOI
  127. Lim, 2017, Somatic mutations in TSC1 and TSC2 cause focal cortical dysplasia, Am J Hum Genet, 100, 454, 10.1016/j.ajhg.2017.01.030 · DOI
  128. Capo-Chichi, 2013, Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly, J Med Genet, 50, 740, 10.1136/jmedgenet-2013-101680 · DOI
  129. Alfaiz, 2014, TBC1D7 mutations are associated with intellectual disability, macrocrania, patellar dislocation, and celiac disease, Hum Mutat, 35, 447, 10.1002/humu.22529 · DOI
  130. Cen, 2017, De novo mutation in DEPDC5 associated with unilateral pachygyria and intractable epilepsy, Seizure, 50, 1, 10.1016/j.seizure.2017.03.014 · DOI
  131. Møller, 2016, Germline and somatic mutations in the MTOR gene in focal cortical dysplasia and epilepsy, Neurol Genet, 2, e118, 10.1212/NXG.0000000000000118 · DOI
  132. Mirzaa, 2012, Megalencephaly-capillary malformation (MCAP) and megalencephaly-polydactyly-polymicrogyria-hydrocephalus (MPPH) syndromes: Two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis, Am J Med Genet A, 158a, 269, 10.1002/ajmg.a.34402 · DOI
  133. Lindhurst, 2011, A mosaic activating mutation in AKT1 associated with the Proteus syndrome, N Engl J Med, 365, 611, 10.1056/NEJMoa1104017 · DOI
  134. Mirzaa, 2016, PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution, JCI Insight, 1, e87623, 10.1172/jci.insight.87623 · DOI
  135. Mirzaa, 2015, Characterisation of mutations of the phosphoinositide-3-kinase regulatory subunit, PIK3R2, in perisylvian polymicrogyria: a next-generation sequencing study, Lancet Neurol, 14, 1182, 10.1016/S1474-4422(15)00278-1 · DOI
  136. Edmondson, 2015, Overgrowth syndromes, J Pediatr Genet, 4, 136, 10.1055/s-0035-1564440 · DOI
  137. Butler, 2005, Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations, J Med Genet, 42, 318, 10.1136/jmg.2004.024646 · DOI · Paper page
  138. Child, 2013, Mystery case: Cowden syndrome presenting with partial epilepsy related to focal cortical dysplasia, Neurology, 81, e98, 10.1212/WNL.0b013e3182a55ef0 · DOI
  139. Shao, 2020, Polymicrogyria is associated with pathogenic variants in PTEN, Ann Neurol, 88, 1153, 10.1002/ana.25904 · DOI
  140. Koboldt, 2021, PTEN somatic mutations contribute to spectrum of cerebral overgrowth, Brain, 10.1093/brain/awab173 · DOI
  141. Basel-Vanagaite, 2013, Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy and dysmorphic corpus callosum, Am J Hum Genet, 93, 524, 10.1016/j.ajhg.2013.07.005 · DOI
  142. Venkatesan, 2016, Early-life epileptic encephalopathy secondary to SZT2 pathogenic recessive variants, Epileptic Disord, 18, 195, 10.1684/epd.2016.0828 · DOI
  143. Baple, 2014, Mutations in KPTN cause macrocephaly, neurodevelopmental delay, and seizures, Am J Hum Genet, 94, 87, 10.1016/j.ajhg.2013.10.001 · DOI
  144. Pajusalu, 2015, Novel homozygous mutation in KPTN gene causing a familial intellectual disability-macrocephaly syndrome, Am J Med Genet A, 167a, 1913, 10.1002/ajmg.a.37105 · DOI
  145. Serkova, 2001, Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain, Br J Pharmacol, 133, 875, 10.1038/sj.bjp.0704142 · DOI
  146. Messina, 2007, Tuberous sclerosis preclinical studies: Timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779, BMC Pharmacol, 7, 14, 10.1186/1471-2210-7-14 · DOI
  147. Schuler, 1997, SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo, Transplantation, 64, 36, 10.1097/00007890-199707150-00008 · DOI
  148. Metcalf, 2004, Structure- based design of AP23573, a phosphorus-containing analog of rapamycin for anti-tumor therapy
  149. Grenier, 2021, Mucocutaneous adverse events associated with oral sirolimus for the treatment of vascular anomalies, JAMA Dermatol, 157, 233, 10.1001/jamadermatol.2020.5180 · DOI
  150. Weiner, 2007, Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome–a single-centre experience and review of the literature, Nephrol Dial Transplant, 22, 3631, 10.1093/ndt/gfm420 · DOI
  151. Rodríguez-Moreno, 2009, Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: Experience in a center, Transplant Proc, 41, 2163, 10.1016/j.transproceed.2009.06.003 · DOI
  152. Lo Muzio, 2018, Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients, Oral Dis, 24, 144, 10.1111/odi.12795 · DOI
  153. Atkinson, 2014, Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: Predictors, management, and outcomes, BJU Int, 113, 376, 10.1111/bju.12420 · DOI
  154. Albiges, 2012, Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma, Ann Oncol, 23, 1943, 10.1093/annonc/mds115 · DOI

Cited by

Sorted by citations

See all 125

Metadata

Authors
Moloney, P. B., Cavalleri, G. L., & Delanty, N.
Affiliations
FutureNeuro, the Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, Dublin, D02 VN51, Ireland
Venue
Brain Communications
Publisher
Oxford University Press (OUP)
Published
2021-09-25
Volume
3
Issue
4
ISSN
2632-1297
DOI
10.1093/braincomms/fcab222
PMC
PMC8495134
Cited by
125
References
16
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review